s6y

Kalaris Therapeutics, Inc.

Ticker
KLRS
CIK
1754068
Industry
Biological Products, (No Diagnostic Substances)
Formerly
Allovir, Inc., ViraCyte, Inc.

Financials 28

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 28 financials filings

News 72

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 72 news filings

Ownership 381

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 3 Initial statement of beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 3 Initial statement of beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 381 ownership filings

Prospectus 37

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. S-3 Registration statement for specified transactions by certain issuers
  4. S-3 Registration statement for specified transactions by certain issuers
  5. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  6. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  9. S-4/A Registration of securities issued in business combination transactions
  10. S-4/A Registration of securities issued in business combination transactions

All 37 prospectus filings

Proxies 15

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEF 14A Definitive proxy statements
  9. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  10. DEF 14A Definitive proxy statements

All 15 proxies filings

Other 168

  1. SCHEDULE 13G
  2. SCHEDULE 13D/A
  3. ARS Annual report to security holders
  4. EFFECT Notice of Effectiveness
  5. EFFECT Notice of Effectiveness
  6. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  7. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  8. UPLOAD Letter (PDF)
  9. UPLOAD Letter (PDF)
  10. 144 Filing for proposed sale of securities under Rule 144

All 168 other filings